Improvement of antithrombotic activity of red ginseng extract by nanoencapsulation using chitosan and antithrombotic cross-linkers: polyglutamic acid and fucodian
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Eun Suh | - |
dc.contributor.author | Lee, Ji-Soo | - |
dc.contributor.author | Lee, Hyeon Gyu | - |
dc.date.accessioned | 2022-07-07T00:32:55Z | - |
dc.date.available | 2022-07-07T00:32:55Z | - |
dc.date.created | 2021-07-14 | - |
dc.date.issued | 2021-03 | - |
dc.identifier.issn | 1226-8453 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/142231 | - |
dc.description.abstract | Background: Red ginseng (RG) extract, especially ginsenoside Rg1 and Rb1 fractions has been reported to have antithrombotic activities. However, gastric instability and low intestinal permeability are considered to be obstacles to its oral administration. We hypothesized that stability, permeability, and activities of RG might be improved by encapsulation within nanoparticles (NPs) prepared with antithrombotic coating materials. Methods: RG-loaded chitosan (CS) NPs (PF-NPs) were prepared by complex ionic gelation with the antithrombotic wall materials, polyglutamic acid (PGA), and fucoidan (Fu). The concentrations of PGA (mg/mL, X-1) and Fu (mg/mL, X-2) were optimized for the smallest particle size by response surface methodology. Antithrombotic activities of RG and PF-NPs were analyzed using ex vivo and in vivo antiplatelet activities, in vivo carrageenan-induced mouse tail, and arteriovenous shunt rat thrombosis models. Results: In accordance with a quadratic regression model, the smallest PF-NPs (286 + 36.6 nm) were fabricated at 0.628 mg/mL PGA and 0.081 mg/mL Fu. The inhibitory activities of RG on ex vivo and in vivo platelet aggregation and thrombosis in in vivo arteriovenous shunt significantly (p < 0.05) increased to approximately 66.82%, 35.42%, and 38.95%, respectively, by encapsulation within PF-NPs. For an in vivo carrageenan-induced mouse tail thrombosis model, though RG had a weaker inhibitory effect, PF-NPs reduced thrombus significantly due to the presence of PGA and Fu. Conclusion: PF-NPs contributed to improve the activities of RG not only by nanoencapsulation but also by antithrombotic coating materials. Therefore, PG-NPs can be suggested as an efficient delivery system for oral administration of RG. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC GINSENG | - |
dc.title | Improvement of antithrombotic activity of red ginseng extract by nanoencapsulation using chitosan and antithrombotic cross-linkers: polyglutamic acid and fucodian | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Hyeon Gyu | - |
dc.identifier.doi | 10.1016/j.jgr.2020.04.001 | - |
dc.identifier.scopusid | 2-s2.0-85084467380 | - |
dc.identifier.wosid | 000632821600005 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GINSENG RESEARCH, v.45, no.2, pp.236 - 245 | - |
dc.relation.isPartOf | JOURNAL OF GINSENG RESEARCH | - |
dc.citation.title | JOURNAL OF GINSENG RESEARCH | - |
dc.citation.volume | 45 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 236 | - |
dc.citation.endPage | 245 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002721658 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Plant Sciences | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Integrative & Complementary Medicine | - |
dc.relation.journalWebOfScienceCategory | Plant Sciences | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Integrative & Complementary Medicine | - |
dc.subject.keywordPlus | acetylsalicylic acid | - |
dc.subject.keywordPlus | adenosine diphosphate | - |
dc.subject.keywordPlus | alanine aminotransferase | - |
dc.subject.keywordPlus | alkaline phosphatase | - |
dc.subject.keywordPlus | arachidonic acid | - |
dc.subject.keywordPlus | aspartate aminotransferase | - |
dc.subject.keywordPlus | bovine serum albumin | - |
dc.subject.keywordPlus | calcium | - |
dc.subject.keywordPlus | carrageenan | - |
dc.subject.keywordPlus | chitosan nanoparticle | - |
dc.subject.keywordPlus | chloride | - |
dc.subject.keywordPlus | cholesterol | - |
dc.subject.keywordPlus | collagen | - |
dc.subject.keywordPlus | creatinine | - |
dc.subject.keywordPlus | fucoidin | - |
dc.subject.keywordPlus | gamma glutamyltransferase | - |
dc.subject.keywordPlus | ginseng extract | - |
dc.subject.keywordPlus | ginsenoside Rb 1 | - |
dc.subject.keywordPlus | ginsenoside Rg 1 | - |
dc.subject.keywordPlus | heparin | - |
dc.subject.keywordPlus | nanoparticle | - |
dc.subject.keywordPlus | phosphate | - |
dc.subject.keywordPlus | polyglutamic acid | - |
dc.subject.keywordPlus | potassium | - |
dc.subject.keywordPlus | sodium | - |
dc.subject.keywordPlus | thromboxane A2 | - |
dc.subject.keywordPlus | triacylglycerol | - |
dc.subject.keywordPlus | acute toxicity | - |
dc.subject.keywordPlus | animal cell | - |
dc.subject.keywordPlus | animal experiment | - |
dc.subject.keywordPlus | animal model | - |
dc.subject.keywordPlus | antiplatelet activity | - |
dc.subject.keywordPlus | antithrombotic activity | - |
dc.subject.keywordPlus | arteriovenous shunt | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | BHK-21 cell line | - |
dc.subject.keywordPlus | clinical assessment | - |
dc.subject.keywordPlus | clinical evaluation | - |
dc.subject.keywordPlus | coating (procedure) | - |
dc.subject.keywordPlus | concentration process | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | cross linking | - |
dc.subject.keywordPlus | cytotoxicity assay | - |
dc.subject.keywordPlus | dispersity | - |
dc.subject.keywordPlus | drug penetration | - |
dc.subject.keywordPlus | drug stability | - |
dc.subject.keywordPlus | enzyme linked immunosorbent assay | - |
dc.subject.keywordPlus | ex vivo study | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | gelation | - |
dc.subject.keywordPlus | ginseng | - |
dc.subject.keywordPlus | in vivo study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | mouse | - |
dc.subject.keywordPlus | nanoencapsulation | - |
dc.subject.keywordPlus | nanopharmaceutics | - |
dc.subject.keywordPlus | nonhuman | - |
dc.subject.keywordPlus | particle size | - |
dc.subject.keywordPlus | physical chemistry | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | rat | - |
dc.subject.keywordAuthor | Antithrombotic activity | - |
dc.subject.keywordAuthor | Chitosan nanoparticle | - |
dc.subject.keywordAuthor | Ionic gelation | - |
dc.subject.keywordAuthor | Platelet aggregation | - |
dc.subject.keywordAuthor | Red ginseng | - |
dc.subject.keywordAuthor | Response surface methodology | - |
dc.identifier.url | https://linkinghub.elsevier.com/retrieve/pii/S1226845320300828 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.